文献速递运动医学关节外科

采用高软骨细胞活性移植物行膝关节骨软骨同种异体移植术的中期结局

Midterm Outcomes After Osteochondral Allograft Transplantation in the Knee Using High-Chondrocyte Viability Grafts.
PubMed 文献 · Am J Sports Med · 2024-10-16

该病例系列纳入137例(134例患者)初次膝关节骨软骨同种异体移植术(OCAT)并使用高软骨细胞活性(HCV)移植物、随访≥5年的病例,中期(5至8年)功能移植物生存率为82%,从胫股双极OCAT的69%到单面单极的97%不等;校正年龄、BMI和吸烟后,同期韧带重建和不依从术后康复方案与失败风险升高相关。

要点

  • 中期(5至8年)功能移植物生存率全部病例合计为82%,胫股双极HCV OCAT为69%,髌股双极89%,多面单极94%,单面单极97%。
  • 校正年龄、BMI和吸烟状态后,不同手术类型未显示失败风险增加,而同期韧带重建和不依从术后康复方案显示失败风险增加。
  • 获得功能移植物生存的患者在PROMIS身体功能与活动能力、国际膝关节文献委员会问卷和单一评估数值评价评分上较需行关节置换者显著更高。

核心结论

  • 使用HCV骨软骨同种异体移植物时,初次膝关节OCAT的中期(5至8年)功能移植物生存率显著高于既往报道的传统OCAT中期生存率。
  • 校正患者特征后,因膝关节不稳行同期韧带重建和不依从处方术后康复方案是与移植物未生存相关的风险因素。
  • 初次OCAT后功能移植物生存≥5年的患者报告疼痛、功能和活动能力有统计学显著且临床有意义的改善。

研究设计与样本

  • 病例系列,证据等级4级。
  • 分析137例初次膝关节OCAT(134例患者),均使用高软骨细胞活性骨软骨同种异体移植物且有≥5年结局数据,平均随访66个月(59例女性,75例男性;平均年龄37.8岁;平均BMI 28.5)。
  • 采用Kaplan-Meier分析评估生存率差异,Cox比例风险模型评估风险因素及多变量关系。

主要发现

  • 中期(5至8年)功能移植物生存率全部病例合计为82%,胫股双极HCV OCAT为69%,髌股双极89%,多面单极94%,单面单极97%。
  • 初次治疗失败率(初次OCAT后翻修或关节置换)和OCAT未生存率(初次或翻修OCAT后关节置换)在年龄较大、同期韧带重建、胫股双极OCAT和不依从处方术后康复方案的患者中更高。
  • 校正年龄、BMI和吸烟状态后,不同手术类型未显示失败风险增加,而同期韧带重建和不依从显示失败风险增加。
  • 获得功能移植物生存的患者在PROMIS身体功能与活动能力、国际膝关节文献委员会问卷和单一评估数值评价评分上显著高于需行关节置换的患者,且终末随访时显著更高。
  • 初次OCAT后疼痛、功能和活动能力的患者报告改善超过最小临床重要差异并持续≥5年。

关键数值与推荐

  • 功能移植物生存率全部病例合计82%(5至8年)。
  • 胫股双极HCV OCAT生存率69%,髌股双极89%,多面单极94%,单面单极97%。
  • 患者满意率:非常满意或满意76.2%,中立8.5%,不满意或非常不满意15.4%。

临床怎么用

  • 作者报告使用HCV骨软骨同种异体移植物行初次膝关节OCAT的中期功能移植物生存率高于既往报道的传统OCAT中期生存率。
  • 作者报告校正患者特征后,因膝关节不稳行同期韧带重建和不依从处方术后康复方案与移植物未生存相关。
  • 作者报告初次OCAT后功能移植物生存≥5年的患者疼痛、功能和活动能力有统计学显著且临床有意义的改善。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Osteochondral allograft transplantation (OCAT) has become a standard-of-care treatment option for patients with large symptomatic articular defects. Recent advances in allograft science and OCAT protocols have been reported to result in consistently robust outcomes after OCAT in the knee. However, only short-term comparisons have been reported, and analyses are lacking for treatment failure risk factors that account for confounding variables. HYPOTHESIS: Midterm functional graft survival rate would exceed 80% for all OCATs combined, with consideration of risk factors for lower survivorship including older patient age, higher body mass index (BMI), tibiofemoral bipolar OCAT, and nonadherence to prescribed postoperative rehabilitation protocols. STUDY DESIGN: Case series; Level of evidence, 4. METHODS: Patients with outcome data available at ≥5 years after primary OCAT using high chondrocyte-viability (HCV) osteochondral allografts were analyzed according to 2 clinically relevant definitions: (1) initial treatment failure, defined by revision or arthroplasty surgery performed for the primary OCAT at any time point during the study period; and (2) functional graft failure, defined by documented conversion to arthroplasty after primary or revision OCAT at any time point during the study period. Analyses were used to assess outcomes for each definition, separately for age group, sex, obesity status, tobacco use, type of OCAT surgery, osteotomy status, concurrent ligament surgery status, and adherence to postoperative protocols. Kaplan-Meier analyses were used to assess differences in survival rates, and Cox proportional hazards models were used to assess risk factors and multivariable relationships with survival. Patient-reported outcome measures for pain, function, mobility, and satisfaction were also analyzed. RESULTS: Analysis included 137 primary knee OCATs performed in 134 patients with a mean follow-up of 66 months (59 female, 75 male; mean age, 37.8 years; mean BMI, 28.5). The midterm (5- to 8-year) functional graft survival rate for patients undergoing primary OCAT in the knee using HCV grafts was 82% for all cases combined, ranging from 69% for tibiofemoral bipolar HCV OCATs to 89% for patellofemoral bipolar, 94% for multisurface unipolar, and 97% for single-surface unipolar. Initial treatment failure rates (revision or arthroplasty after primary OCAT) and OCAT nonsurvival rates (arthroplasty after primary or revision OCAT) were greater for older patient age, concurrent ligament reconstruction, tibiofemoral bipolar OCAT, and nonadherence to the prescribed postoperative rehabilitation protocols. When adjusted for patients' age, BMI, and tobacco use status, different surgery types did not demonstrate an increased risk for failure, while concurrent ligament reconstruction and nonadherence did. Patients who experienced functional graft survival after primary OCAT reported significantly greater improvements in PROMIS Physical Function and Mobility (Patient-Reported Outcomes Measurement Information System), International Knee Documentation Committee questionnaire, and Single Assessment Numeric Evaluation scores such that they were significantly higher at final follow-up as compared with patients who required arthroplasty. Patient-reported improvements in pain, function, and mobility exceeded minimal clinically important differences for ≥5 years after primary OCAT. When asked if they were satisfied with primary OCAT surgery, 76.2% of patients were very satisfied or satisfied with their results, while 8.5% were neutral and 15.4% were unsatisfied or very unsatisfied. CONCLUSION: With use of HCV osteochondral allografts, midterm (5- to 8-year) functional graft survival rates for patients undergoing primary OCAT in the knee were notably higher than previously reported midterm rates for traditional OCATs. When adjusted for patient characteristics, risk factors for nonsurvival included concurrent ligament reconstruction for knee instability and nonadherence to the prescribed postoperative rehabilitation protocols. Patients who experienced functional graft survival for ≥5 years after primary OCAT reported statistically significant and clinically meaningful improvements in pain, function, and mobility.

来源:Am J Sports Med,查看原文。版权归原作者所有。

引用

  1. Cook JL, Rucinski K, Leary EV, et al. Midterm Outcomes After Osteochondral Allograft Transplantation in the Knee Using High-Chondrocyte Viability Grafts. Am J Sports Med. 2024. PMID: 39415346. doi:10.1177/03635465241285457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。